Welcome to our dedicated page for HYPERFINE news (Ticker: HYPR), a resource for investors and traders seeking the latest updates and insights on HYPERFINE stock.
Hyperfine, Inc. develops and commercializes the Swoop® system, an FDA-cleared, AI-powered portable ultra-low-field magnetic resonance brain imaging system. News about HYPR centers on Swoop deployments across hospitals, emergency departments, ICUs, neurology offices, and international markets; regulatory clearances such as CE and UKCA marks; and Optive AI™ software updates tied to brain imaging workflows.
Company updates also cover quarterly results, clinical data and publications in stroke and neuroimaging, distributor and customer activity, financing arrangements, and healthcare-conference participation.
Hyperfine (Nasdaq: HYPR) launched its next-generation Swoop® portable MRI (Model 2) in Europe, powered by updated Optive AI™ software. Following CE mark and UKCA approvals, the system is commercially available in initial European markets and listed on France’s UniHA procurement platform, supporting the company’s 2026 international commercialization strategy.
Hyperfine (Nasdaq: HYPR) formed a Global Neurosurgery Advisory Council to support expansion of its Swoop® portable, ultra-low-field, AI-powered brain MRI system in neurosurgical care.
The multidisciplinary group of leading neurosurgeons will guide workflow integration, product development, and clinical evidence generation across preoperative, intraoperative, and postoperative settings.
Hyperfine (Nasdaq: HYPR) reported record U.S. scan volumes for its FDA-cleared AI-powered portable brain MRI, the Swoop® system, across hospitals and neurology clinics.
Key sites surpassed 1,000 and 500-scan milestones, showing expanding clinical use in ICUs, EDs, operating rooms, and outpatient neurology practices, with reported benefits in patient access, wait times, and hospital efficiency.
Hyperfine (Nasdaq: HYPR), developer of the FDA-cleared AI-powered portable brain MRI Swoop system, is expected to join the Russell 3000 and Russell 2000 indexes after the U.S. market close on June 26, 2026, following the June 2026 Russell reconstitution.
Membership in the Russell 3000 is set for six months under the new semi-annual schedule. Russell U.S. indexes are widely used benchmarks, with about $12.2 trillion in assets linked to them as of June 2025.
Hyperfine (Nasdaq: HYPR) reported results from the single-center randomized PRIME study of its Swoop portable MRI in emergency departments.
Portable MRI reduced median order-to-scan time to 1.28 hours vs 7.76 hours, detected critical pathology in 18.6% of scans, and all findings were confirmed on conventional MRI.
Hyperfine (Nasdaq: HYPR) reported strong Q1 2026 results and strategic milestones for its Swoop® portable MR brain imaging system.
- Q1 revenue $3.90M, up 83% YoY; 10 systems sold
- Gross margin 51% vs 41% YoY
- Net loss $8.62M ($0.09/share), narrower YoY
- R&D expenses down 24% to $3.85M
- Secured $15M debt financing, extending expected cash runway into 2028
- Obtained CE Mark and UKCA for next-gen Swoop® and Optive AI™; launched first system in India
- 2026 revenue guidance $20–22M; cash burn guidance $26–28M
Hyperfine (Nasdaq: HYPR) will present at the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, 2026 at 8:45 AM ET. A live audio webcast and archived recording will be available on the company’s Investors page. Management will also hold in-person meetings; scheduling is via Jefferies or the investor contact.
Hyperfine (NASDAQ: HYPR) announced clinical use of the Swoop® portable MRI at All India Institute of Medical Sciences, New Delhi—the first bedside MRI deployed for routine clinical brain imaging in India. Radiosurgery Global is the exclusive distributor; AIIMS will use the system for stroke, ICU, trauma, neonatal, pediatric and neurosurgical care and clinical research.
Hyperfine (Nasdaq: HYPR) will report first-quarter 2026 financial results on Tuesday, May 12, 2026. Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET with a live audio webcast and archived recording available on the company’s Investors page. Participants should register at least 15 minutes early.
Hyperfine (Nasdaq: HYPR) received CE Marking and UKCA approval for its next-generation Swoop® system and the latest Optive AI™ software, enabling commercialization across the European Economic Area and the United Kingdom.
The next-generation Swoop, FDA-cleared in Q2 2025, delivers improved image quality and workflow; Optive AI adds multi-direction DWI for better small-stroke detection. Commercial launch in Europe and the UK is planned early Q3 2026.